Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 25.7%

Key Points

• Short interest in Armata Pharmaceuticals decreased by 25.7% in August, totaling 36,800 shares as of August 31st.
• A hedge fund, GSB Wealth Management LLC, purchased 30,000 shares of Armata Pharmaceuticals, valued at approximately $57,000, increasing institutional ownership to 3.57%.
• The stock of Armata Pharmaceuticals rose by 2.4% on Wednesday, reaching a price of $2.95, with a twelve-month trading range between $0.90 and $3.14.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the target of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 36,800 shares, a decrease of 25.7% from the August 15th total of 49,500 shares. Based on an average daily volume of 15,200 shares, the short-interest ratio is presently 2.4 days. Approximately 0.3% of the company's shares are sold short. Approximately 0.3% of the company's shares are sold short. Based on an average daily volume of 15,200 shares, the short-interest ratio is presently 2.4 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Armata Pharmaceuticals stock. GSB Wealth Management LLC purchased a new stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 3.57% of the company's stock.

Armata Pharmaceuticals Stock Up 3.0%

Shares of NYSEAMERICAN ARMP traded up $0.09 during mid-day trading on Friday, hitting $3.07. 12,650 shares of the company traded hands, compared to its average volume of 11,255. Armata Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $3.14. The stock has a market capitalization of $111.23 million, a price-to-earnings ratio of -2.98 and a beta of 1.09. The business has a 50 day moving average of $2.60 and a two-hundred day moving average of $2.01.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.